Navigation Links
VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
Date:12/20/2007

Qualification will satisfy closing condition to merger with Raven

biotechnologies

SOUTH SAN FRANCISCO, Calif., Dec. 20 /PRNewswire-FirstCall/ -- VaxGen Inc. (Pink Sheets: VXGN), a biopharmaceutical company, announced today that it has, along with Punk Ziegel and Company, begun the process of qualifying its shares of common stock for quotation on the OTC Bulletin Board, and is expected to commence trading by the end of the year under the symbol VXGN. Further, VaxGen and Raven biotechnologies, inc. have amended the merger agreement between the two companies to clarify that VaxGen's qualification on the OTC Bulletin Board satisfies the closing condition to the proposed merger between VaxGen and Raven requiring that VaxGen be listed on an approved trading market.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

Commenting, James P. Panek, VaxGen's CEO, said "In addition to the benefits of increased liquidity, we are very pleased that the qualification on the OTC Bulletin Board eliminates a source of uncertainty related to our proposed merger with Raven biotechnologies. In talking with both current and prospective stockholders, it became clear that concern over this closing condition was creating unnecessary uncertainty and was distracting from the merits of the deal. We believe that the proposed merger with Raven represents an excellent opportunity for the Company's stockholders."

Matthew Pfeffer, VaxGen's Chief Financial Officer added: "It remains our goal to list on NASDAQ or another national exchange at the appropriate time, and we plan to proceed with a 5:1 reverse split of our common stock, subject to stockholder and board approval, to facilitate such a listing."

The Company is seeking approval to undertake the planned reverse split at its annual meeting of stockholders scheduled for December 2
'/>"/>

SOURCE VaxGen
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
3. VaxGen Files First Quarter 2007 Financials
4. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
5. VaxGen Files Last Outstanding Periodic Report With SEC
6. VaxGen Addresses MPM Claims in Letter to Stockholders
7. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
8. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
9. Viragen International to Reverse Split Its Common Stock
10. Exelixis Announces Closing of Public Offering of Common Stock
11. BioMed Realty Trust Declares Third Quarter 2007 Common Stock and Preferred Stock Dividends
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused ... analysis of tumor cells in the bloodstream, today announced ... decision support application powered by CollabRx, Inc. , ... test, Therapy Finder will provide breast cancer patients and ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 More than ... and about 1 in 3 seniors will die with ... ). These jaw-dropping figures have shocked many Americans into ... hopefully, help prevent these tragic age-related cognitive disorders. Jonathan ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider of ... one of India’s top five pharmaceutical companies, has received ... for high throughput solid form screening. , Lupin, ... range of quality, affordable generic and branded formulations and ...
(Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... based on the products of cells grown under simulated ... an international license agreement with Suneva Medical, Inc. for ... media (CCM). , This agreement is an ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... they,ve been miniaturized to take up less space and ... data conversion electronics on the James Webb Space Telescope ... convert analog signals to digital signals and provide better ... "SIDECAR" have been miniaturized from a volume of about ...
... Feb. 20 Kensey Nash Corporation,(Nasdaq: KNSY ... clearance for an,important vessel wall detection technology from ... the guidance provided by the,Safe-Cross(R) RF CTO System. ... radio frequency (RF) energy to safely,cross and recanalize ...
... Calif., Feb. 20 5AM Ventures, specializing,in seed ... announced the expansion of the firm,s investment team ... Partner. 5AM Ventures,also announced the promotion of two ... and R. Andrew McMillan, PhD, to Principal. Drs. ...
Cached Biology Technology:Amazing minaturized 'SIDECAR' drives Webb telescope's signal 2Amazing minaturized 'SIDECAR' drives Webb telescope's signal 3Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology 2Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology 3Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology 4Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology 55AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal 25AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal 3
(Date:4/17/2014)... , Respiratory syncytial virus (RSV) is a leading ... illness in very young and elderly populations. Despite ... host cells through the fusion protein RSV F, ... peptides that prevent bundle formation limit RSV infection ... to degradation. In this issue of the ...
(Date:4/17/2014)... Luca Razzari of the nergie Matriaux Tlcommunications Research ... the John R. Evans Leaders Fund of the ... of state-of-the-art biotech and nanophotonics equipment. To this ... Ministre de l,Enseignement suprieur, de la Recherche, de ... new laboratories will help us develop new approaches ...
(Date:4/17/2014)... need to produce hydrogen sulfide in order to properly ... study from the Center for Craniofacial Molecular Biology at ... Professor Songtao Shi, principal investigator on the project, said ... governs the flow of calcium ions. The essential ions ... osteogenesis, or the creation of new bone tissue, and ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... University of North Carolina at Chapel Hill have purified a ... by reversing a molecular modification previously thought permanent. , In ... is able to remove a methyl group from histone H3, ... just last year, the addition of a methyl group to ...
... Hospital of Philadelphia leads a multi-center $6.7 million program ... Mental Health (NIMH) to explore a novel approach to ... and clinical trials in adult patients, the new grant ... immunodeficiency virus: sites on immune cells known as neurokinin-1 ...
... the work of machines that contain dozens of molecules, chiefly ... now have a nearly complete "parts list" of such machines; ... pieces go. A new study by scientists at the European ... some of the smallest and trickiest components in the cellular ...
Cached Biology News:Novel enzyme offers new look at gene regulation 2Federal grant funds research on novel HIV therapy 2Federal grant funds research on novel HIV therapy 3Many needles, many haystacks 2
Porcine parvovirus and mycoplasma tested. Contains 0.5 g/L of trypsin (1:250) and 0.2 g/L of EDTA4Na in Hanks' Balanced Salt Solution without CaCl2 MgCl2 6H2O and MgSO4 7H2O. Contains phenol red....
...
... pPIC9K and pPIC3.5K vectors carry the kanamycin ... Reagent in Pichia. Spontaneous generation of multiple ... to increased levels of Geneticin Reagent. Pichia ... screened for their level of resistance to ...
Immunogen: Synthetic peptide: R(89) L A F T V D D N P T K P T T R Q R Y(107) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: